News & Progress
Press Releases
Posters & Publications
Poster HYDRA Platform Development to Investigate Siglec-engaging Tumor Immunosuppressive Glyco-codes Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 9, 2019, Abstract #P118 Poster Blockade of Siglec/Sialoglycan Axis Using EAGLE Technology to Potentiate Anticancer Immunity Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting, November 8, 2019, Abstract #P273 Publication Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment Cancer Immunology Research. April 23, 2019. Poster A Novel Therapeutic Modality of Inhibiting the Glyco-Immune Checkpoint Axis to Treat Cancer American Association for Cancer Research, April 2019, Poster #LB-109 Poster A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology American Association for Cancer Research, November 2018 Poster Targeting Tumor Sialylation in Combination with Checkpoint Inhibitors for Cancer Immunotherapy Society for Immunotherapy of Cancer, November 2018, Poster #676 Poster A Novel Immunomodulatory Strategy of Targeting Glyco-Immune Checkpoints with EAGLE Technology Society for Immunotherapy of Cancer, November 2018, Poster #037 Publication Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells Journal of Clinical Investigation. August 21, 2018.
Social Media
@Palleon_Pharma • Jan 15, 2020
Palleon is inspired by all who are living with #CervicalCancer and those who devote their lives to caring for patie… http://QIwZIyUrMg
@Palleon_Pharma • Jan 13, 2020
Our Founder and CEO, Jim Broderick, M.D., SVP of Research and Early Product Development, Li Peng, Ph.D., and Associ… http://RxtwxCQXKI